Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How about this. Appel and Khleif were only two BOD members who did not participate in the insider buys 3 months ago. Now that Appel did, let's wait for Samir Khleif to make some open market purchases.
Again, those buys were nothing but an orchestrated attempt to pump the stock price. The money they put into those buys are not that significant on the scale of their compensation. So, why not?
Possible. However, to refresh your mind, there were several insider buys 3 months ago. Those were open market purchases at $1.80 and slightly above. The message board reaction was "the management team has confidence in the company and its future, thus they put their hard earned cash into the company's stock to show a support...". Some were saying that no imminent deals/partnerships on the horizon. Now you know who was right and who was wrong.
This time around, Appel did not buy directly, but his shadow company participated in the recent secondary. Retail would not get a sniff of those shares. Is this different than buying in the open market? Of course. Unless he shorted ahead of the secondary, he's under water. Do his buys show confidence in the company? Yes, of course. But two other points that need to highlighted:
1. No one else from the top management participated in the recent secondary and/or bought shares after the secondary.
2. Appel's buy constitutes an insider trading which is manifested by filing Form 4. Therefore, he knew there are no imminent deals in the making. I find it hard to believe that the BOD member does not know about what's cooking.
@wmtgreeter
This participation in the recent secondary implies there are no material news on the short term horizon. Plain and simple. Otherwise, Appel would have committed a security fraud.
https://www.nasdaq.com/symbol/adxsw/historical
I do not follow the warrants, just noticed they traded below penny at some point after the secondary was announced.
Date Open High Low Close / Last Volume
16:00 0.02 0.12 0.0113 0.035 61,864
09/12/2018 0.0332 0.0332 0.0208 0.021 13,566
09/11/2018 0.007 0.0473 0.007 0.0473 9,478
09/10/2018 0.0475 0.0475 0.0473 0.0473 19,400
09/07/2018 0.05 0.0503 0.04 0.048 174,488
The only RS Group LLC I found was this (on manta):
Rs Group LLC is a privately held company in Mount Pleasant, SC and is a Single Location business.
Categorized under Business Services (Unclassified). Our records show it was established in 2010 and incorporated in South Carolina. Current estimates show this company has an annual revenue of 47000 and employs a staff of approximately 1.
--------------------------------------
Call me impressed.
That's not an open marker purchase, rather, his other company participated in the secondary.
Interesting that the ADXSW warrants were trading sub penny, huge volume. Looks like they are dead as well... I'm lucky not to hold any warrants.
It's mystery who bought newly issued shares during the last secondary (as if that wasn't the case for the previous raise...). New Form 4's should have been reported within 2 business days, and there are none. We likely need to wait for 11/15 to see who bought and who sold. Interestingly, neither Adage nor Amgen are insiders any more provided they did not buy this time. Likely, multiple buyers, and most of them, if not all, are vicious predators. Think CVI, a trading arm of Susquehanna. They feast on the companies like Advaxis. The real manipulation has started few days ago when new shares and warrants were issued. Ken needs to get a monetary deal fast, otherwise the predators are going to eat us alive.
If the management was confident at $1.80, why not show double confidence now and buy shares with both fists? Disappointed no insider buys...
Bill O'Reilly's new book "Killing Advaxis". Coming to your bookstores this December.
They've made a lot of wrong decisions that did a lasting damage (hope not lethal) to the company and the shareholders. EMA submission and withdrawal was one of those. The other, timing of AXAL and NEO/HOT, AXAL's next gen platform, to move to the clinics. The poor timing made AXAL platform obsolete and significantly reduced any interest from the BP.
The other, most critical mistake the management made was prematurely selling out the NEO platform. Amgen got an entire platform fro song and a dance, literally. They got a very cheap long term option on this possibly revolutionary platform, and stand to lose almost nothing but gain billions and billions if this platform works. Advaxis' management should have done the following:
1) Sell/partner NEO indication-by-indication, not an entire platform. This is what they are trying to do now with HOT, however, the precedent was set two years ago with Amgen and now it's rather difficult to make a case for HOT. Thus, the management is trying to take the 1st indication to the clinics and get data, then partner.
2) Advaxis had cash to run 1st NEO trial by themselves. They did not, and got duped. Now that the cash is extremely tight they walk very tight rope with HOT.
3) Delaying public statements about the next gen platforms would have allowed then to sell/partner AXAL without any significant pressure. Poor business strategy based on myopic vision of the top management and their narcissistic desire to be the top show in the biotech.
I think this NEO debacle was an ultimate reason for pushing O'Connor out.
MC is a pathetic $54M. The markets assign zero enterprise value to the science.
When folks here say "The Science is still intact, or, I'm here for the Science", one must ponder how many here on this board do really understand the science behind this company. I'd say, 1% or less. The rest, or 99%, have no clue about the actual science, and I'm in that camp. Now the question would be how those 99-percenters can make those statements about what they do not understand or do not know?
Even the 1%ers, who have advanced medical or biochemical degrees and know the landscape pretty well, are in no position to know whether this science will work out or not. I bet even Dr Petit will not be able to say with 100% confidence that this is a slam dunk. This has been a gamble and will remain a gamble for some time.
Oncosec moves to Pennington, NJ:
ONCS moves into an old house which used to be a city's fire department. Very symbolic move...
Snip: "Dan O’Connor and Sara Bonstein pairing up in top leadership roles at OncoSec is an encore performance for them.
The company’s CEO and chief financial officer were in the same exact roles at Advaxis, a Princeton-based cancer immunotherapy company. They were also both in senior roles at ImClone Systems.
Bonstein said she’s hopeful that aids them in creating a third biopharma industry success story.
“Like any industry, being able to work cohesively together as leaders is critical, and a trust factor is hugely important in that,” she said. “In order to be successful, you have to march to the same beat. We’re able to do that as we reunite here at OncoSec.”
https://www.roi-nj.com/2018/08/02/real_estate/the-jersey-factor-why-did-oncosec-medical-a-leader-in-immunotherapy-relocate-to-n-j/
That was copyrighted by @wmgreeter
#itwasme
Just a prayer was offered.
#hope&prayer
#hopeandchange
Short interest was down by another 150K shares as of 8/31/18. Down to 2.278M shares. That was before this most recent secondary. I thought the SI might have spiked before the secondary.
“We are committed to exploring AXAL in head and neck cancer and are looking at cost-efficient ways to do so. We are actively discussing with third parties.”
———————————————-
After reading Dajani’s response several times, especially this last paragraph, it occurs to me she they are in talks only regarding H&N cancer, not Aim2cerv. The cervical could be continued if they get enough money to run head and neck studies. On the other hand, she could have misstated her thoughts as English may not be her native language.
PS. This is an interpretation made by a GED holder.
Then, in your opinion, what is the reason for the stock crashing yesterday? How do you explain the weakness of the stock?
“A very cheap lottery ticket”
———————————-
We all have heard this when the stock was above $10, at $5, at $3, at $1.50. It could be that one could buy two lottery tickets soon for the price of one, you never know.
This equity has been a gamble, and is a long shot gamble now. So far, the house has been winning and we have been losing the shirts. If the story has changed recently, it only changed for the worse. The management is left with fewer and fewer options on the table, and most of them are not in favor of the legacy shareholders.
You have better chances of hitting a jack pot playing in a casino than this game. I would not put any penny in this equity until I see a sea of change in the management style.
Zat,
Maybe it’s time for you to replace your sticky keyboard. It was malfunctioning when you created your ihub account, and it still is glitching now resulting in the double posting.
Yesterday sell off was a reaction to the quarterly report, little doubt about it. The volume was double of the previous day’s trading. Some remaining funds decided to dump some shares as the management decided not to have a call and provide an update on the state of the business. Attempts to explain the cancellation of the conference call to save money is ridiculous. Ken got his 150K bonus and they now want to save some 10K by canceling the call? They were supposed to provide an update on Axal. No mention of it. This means they let it die quietly. No obituaries.
Wouldn’t be surprised to see Adage reducing their share count by another million or so. We might again see a deficit of the issued shares that disappear into obscurity.
Nice to hear this from a poster who talks non-stop about manipulation, HFT, algos, shorts, and etc. Yes, $0.86 is a random number, of course.
End of rant, last post for the day.
Let's see if $0.86 target holds or momentum traders take the share price a little lower.
What's missing in this share price collapse is the massive, well-organized support from this message board. Instead of predicting doom and gloom accurately, the board members - both paid and nonpaid -- need to start posting extremely positive messages citing new positive developments with the company, highlight the company's top management's vision of the future for immuno-therapy, and emphasize their dedication to cure cancer, not their mis-construed greed and self-enrichment. This should tremendously encourage the hedge funds to open their eyes and then their wallets and start buying this stock in huge chunks.
#nopasaran!
Maybe, a reverse split is a good thing after all?
Vivus (VVUS) is on tears today, up 7%, after the 10:1 reverse split. They've been sub $1 for over a year.
Life is full of surprises...
Are you saying we all got adwaxed in the rear?
First round goes to the latter, unanimous decision. KB's nose completely bloodied, multiple stitches on the eyebrows...
2b//!2b that is the question. @wmtgreeter
Batermere looks a genius now that he sold more than 80% of his shares. His level of education clearly beats mine...
#DDSvsGED
The stock half life was 10 months two years ago, now down to 7 months...
$14.40 a week of 8/8/16
$7.20 a week of 6/12/17
$3.60 a week of 10/23/17
$1.80 a week of 2/20/18
$0.90 a week of 9/10/18
The rate of self-destruction is unparalleled even in the world of highly radioactive materials...
#highlytoxic
The amount of cash they raised this time extends their cash runway for 4 months provided the cash burn rate stays at the Q2 levels. I doubt this will be the case as they will likely take the 1st HOT indication to the clinics on their own thus the burn rate will increase. Realistically, they'll need to refuel sometime by the end of '18 or early '19 to stay away from empty tank.
EZcash:
Retired? Nah. I'm a @wmtgreeter, and had a side job her which pays $1.49 per post. Few days ago, I was let go as my employer is in the process of changing the trajectory for ADXS stock. Does it satisfy your curiosity?
If the saying "Brevity is the soul of wit" is correct, it suggests that you need to stop writing 45,000-word long ramblings each time you post as it exposes you...
Interesting... Dr Reese who supervised ADXS-NEO is moving up in Amgen's corporate ladder. More visibility for this platform?
After the recent success with AMG-420, anti-BCMA antibody contstruct for multiple myeloma, they might be doing thing right?
From Amgen web site:
"An Investigational New Drug application for ADXS-NEO was accepted by the FDA in March 2017, paving the way for the start of phase 1 studies. “We look forward to our continued work with Advaxis to explore the ground-breaking potential of ADXS-NEO in the clinic and across multiple tumor types,” said David Reese, Amgen’s senior vice president for Translational Sciences."
Amgen Announces Succession Plans For Two Executive Officers
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.
After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen, has been appointed as executive vice president of Research and Development, effective today. Reese will report to Robert A. Bradway, chairman and chief executive officer. Harper will remain at Amgen for a period of time to facilitate the transition to Reese.
n his new role, Reese, 55, assumes full responsibility for Amgen's global Research and Development activities. Since joining Amgen in 2005, Reese has served in a breadth of leadership roles, including in Development, Medical Sciences, as head of Discovery Research and in Translational Sciences, where he had responsibility for introducing all of Amgen's early medicines into clinical development. Prior to joining Amgen, Reese served on the faculty at the University of California, Los Angeles (UCLA) and the University of California, San Francisco. In addition, he was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Research International (TORI), a not-for-profit academic clinical research organization. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed his training in Internal Medicine and Hematology/Oncology at the UCLA School of Medicine. Reese has published extensively in the fields of clinical research and translational medicine.
I hope you convey your frustration with the management to Ken as you planned to speak with him this week. Did you get a chance to call him? Anything to share?
Yes, we are all left to speculate as the company decided not to provide us with the update. Shame.
I'm not so sure this can be spun in a positive way, though. The absence of the call itself is puzzling, to say the least.They could be hammering out the deal for AXAL, anything is possible, but the lack of update... Deja-vu all over again. Remember how quietly some programs/partnerships were relegated in obscurity?
RIP, Terry.
Your wisdom will be missed greatly.
Last time around it was shorts who forced the secondary. Now, it’s predatory sharks. Advaxis management has nothing to do with the last offerings. Correct?
If I were the Advaxis management, what better excuse could I come up with?
As expected, no revenue from NEO. No milestone payment for dosing the first patient. Geezus....
Posted this to the biotech value board by replying to Dew’s message. RePosting here.
Dew,
How can you explain this:
They had $58.8M in cash, cash equivalents, and short term investments as of 4/30/18.
As of 7/31/18, they had $40.4M in cash and cash equivalents, and 0 in short term investments. They could have sold those STIs.
This means, they burned $18.4M per quarter, not $14M., right?
Something doesn’t add up.
Dew,
How can you explain this:
They had $58.8M in cash, cash equivalents, and short term investments as of 4/30/18.
As of 7/31/18, they had $40.4M in cash and cash equivalents, and 0 in short term investments. They could have sold those STIs.
This means, they burned $18.4M per quarter, not $14M., right?
Something doesn’t add up.
This is a great sign that we are on a verge of buyout!
They seem to be extremely pre-occupied hammering out the last details of the final deal and have absolutely no time to clean up their voice mail.